Chester County News and Community Website
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) announced the first patient has been dosed in its Phase 3 liMeliGhT clinical trial for OCU400, a gene therapy candidate for retinitis pigmentosa …
Ocugen Doses First Patient in Phase 3 Trial for Retinitis Pigmentosa Therapy Read More
WASHINGTON, D.C. — The Biomedical Advanced Research and Development Authority (BARDA) has announced up to $500 million in funding under Project NextGen to advance clinical trials of novel COVID-19 vaccines …
BARDA Allocates $500 Million for Innovative COVID-19 Vaccine Trials Read More
MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has announced promising results from its recent Phase II/III clinical trial for its lead drug candidate, Buntanetap, targeting Alzheimer’s disease (AD). The …
Annovis Bio’s Alzheimer’s Drug Shows Promise in Phase II/III Trial Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) announced a positive outcome from the Data and Safety Monitoring Board (DSMB) review of its Phase 1/2 ArMaDa clinical trial for OCU410, a …
Ocugen’s Gene Therapy Shows Promise in Early Trial for Age-Related Macular Degeneration Read More
PHILADELPHIA, PA — Salient medical exploration at The Wistar Institute may have shed light on the role of the Epstein-Barr Virus (EBV) in the development of multiple sclerosis (MS). Paul …
Unlocking Epstein-Barr Virus Secrets: Potential Breakthrough in Battle Against Multiple Sclerosis Read More
MALVERN, PA — YPrime has unveiled a new glucometer functionality that integrates seamlessly with its electronic Clinical Outcome Assessment (eCOA) platform. This innovation, developed alongside diabetes patients, aims to revolutionize …
YPrime Launches Groundbreaking Glucometer Feature for Clinical Trials Read More MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) announced a significant milestone in its research with the publication of a new article in the journal Biomolecules. The study focuses on …
Annovis Bio Publishes Key Study on Posiphen Drug Across Species Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focusing on innovative therapies, announced the completion of dosing in the second cohort of its groundbreaking GARDian clinical trial for …
Ocugen Advances with Phase 1/2 Trial for Stargardt Disease Treatment Read More
MALVERN, PA — At the recent American Urological Association (AUA) annual meeting held from May 3-6, 2024, Endo, Inc. took the spotlight with the unveiling of new research on Peyronie’s …
Innovations in Peyronie’s Disease Treatment Highlighted at AUA Annual Meeting Read More
WAYNE, PA — Teleflex Incorporated (NYSE: TFX) announced this week new research findings that highlight the benefits of the Prostatic Urethral Lift (PUL) using the UroLift™ System for benign prostatic …
New Research Sheds Light on Superior Patient Experience with UroLift System in Prostate Treatment Read More